AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7002705 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated instant coffee at pH 4.5
Number of subjects: 36
Study 7002705 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated instant coffee at pH 7.0
Number of subjects: 36
Study 7002705 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated instant coffee at pH 4.5 with mixed nutrient test meal
Number of subjects: 36
Study 7002705 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated instant coffee at pH 7.0 with mixed nutrient test meal
Number of subjects: 36
Study 7002705 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated instant coffee at neutral pH with mixed nutrient test meal
Number of subjects: 36
Study 29357777 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute poisoning patients
Number of subjects: 277
Study 29357777 — intervention group
Group type: COMPARATOR
Intervention: Control patients (nonpoisoned)
Number of subjects: 277
Study 29357777 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 277
Study 29357777 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxic alcohols
Number of subjects: 277
Study 29357777 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 277
Study 29579015 — intervention group
Group type: EXPERIMENTAL
Intervention: aVOR app
Number of subjects: 113
Study 29579015 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional practice)
Number of subjects: 113
Study 26253255 — intervention group
Group type: EXPERIMENTAL
Intervention: cediranib
Number of subjects: 29
Study 24552803 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal oxygen supplement (OS)
Number of subjects: 20
Study 24552803 — intervention group
Group type: COMPARATOR
Intervention: Placebo (compressed air)
Number of subjects: 20
Study 22713287 — intervention group
Group type: COMPARATOR
Intervention: Cinaciguat (50, 100, and 150 µg/h) in COMPOSE 1
Number of subjects: 74
Study 22713287 — intervention group
Group type: COMPARATOR
Intervention: Cinaciguat (not specified dosage) in COMPOSE EARLY
Number of subjects: 74
Study 22713287 — intervention group
Group type: COMPARATOR
Intervention: Cinaciguat (10 and 25 µg/h) in COMPOSE 2
Number of subjects: 74
Study 20439630 — intervention group
Group type: EXPERIMENTAL
Intervention: t(8;21)
Number of subjects: 454
Study 20439630 — intervention group
Group type: EXPERIMENTAL
Intervention: inv(16)
Number of subjects: 454
Study 20439630 — intervention group
Group type: EXPERIMENTAL
Intervention: t(15;17)
Number of subjects: 454
Study 20439630 — intervention group
Group type: EXPERIMENTAL
Intervention: t(8;21) with additional aberrations apart from del(9q) or -X/-Y
Number of subjects: 454
Study 20439630 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex karyotype
Number of subjects: 454
Study 20439630 — intervention group
Group type: EXPERIMENTAL
Intervention: Monosomy 7
Number of subjects: 454
Study 20439630 — intervention group
Group type: COMPARATOR
Intervention: Remaining patients with cytogenetic data
Number of subjects: 454
Study 20439630 — intervention group
Group type: EXPERIMENTAL
Intervention: MLL rearrangement
Number of subjects: 454
Study 20439630 — intervention group
Group type: EXPERIMENTAL
Intervention: t(9;11) with additional aberrations
Number of subjects: 454
Study 20439630 — intervention group
Group type: EXPERIMENTAL
Intervention: MLL rearrangements other than t(9;11) and t(11;19)
Number of subjects: 454
Study 20439630 — intervention group
Group type: EXPERIMENTAL
Intervention: Aberrations in 12p
Number of subjects: 454
Study 20439630 — intervention group
Group type: EXPERIMENTAL
Intervention: Aberrations of chromosome 5
Number of subjects: 454
Study 17913322 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium administration for two weeks
Number of subjects: 8
Study 16002915 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol 2.5 mg
Number of subjects: 86
Study 16002915 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized albuterol 5 mg
Number of subjects: 86
Study 16002915 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal bronchodilation (Emax) FEV(1)
Number of subjects: 86
Study 16002915 — intervention group
Group type: EXPERIMENTAL
Intervention: Emax PEFR
Number of subjects: 86
Study 11985738 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (specific interventions not detailed)
Number of subjects: 616
Study 11985738 — intervention group
Group type: COMPARATOR
Intervention: Eligible but did not participate
Number of subjects: 616
Study 10070817 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of fibrinogen in patients with high baseline fibrinogen levels
Number of subjects: 0
Study 10070817 — intervention group
Group type: COMPARATOR
Intervention: Baseline fibrinogen levels
Number of subjects: 0
Study 10070817 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of fibrinogen
Number of subjects: 0
Study 7673546 — intervention group
Group type: EXPERIMENTAL
Intervention: Short‐Term Dynamic Psychotherapy (STDP)
Number of subjects: 0
Study 7673546 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Adaptive Psychotherapy (BAP)
Number of subjects: 0
Study 1710624 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 IU GH administered intramuscularly on alternate days starting on cycle day 4
Number of subjects: 16
Study 1710624 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile saline) administered intramuscularly on alternate days starting on cycle day 4
Number of subjects: 16
Study 1710624 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 IU GH administered intramuscularly
Number of subjects: 16
Study 1710624 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile saline)
Number of subjects: 16
Study 6798616 — intervention group
Group type: COMPARATOR
Intervention: Alprazolam (0.25, 0.5, and 1.0 mg)
Number of subjects: 16
Study 6798616 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (2, 5, and 10 mg)
Number of subjects: 16
Study 31994365 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone (10 mg)/Naloxone (5 mg) for the first 48 hours
Number of subjects: 83
Study 31994365 — intervention group
Group type: COMPARATOR
Intervention: Morphine (0.2-0.4 mg/kg/day)
Number of subjects: 83
Study 31422852 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery Rescripting (IR)
Number of subjects: 104
Study 31422852 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal Exposure (IE)
Number of subjects: 104
Study 29862734 — intervention group
Group type: EXPERIMENTAL
Intervention: Kerr resin filler
Number of subjects: 126
Study 29862734 — intervention group
Group type: COMPARATOR
Intervention: Ordinary resin filler
Number of subjects: 126
Study 25373836 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient requests for diagnostic tests
Number of subjects: 824
Study 25373836 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient requests for pain medications
Number of subjects: 824
Study 25373836 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient requests for specialist referrals
Number of subjects: 824
Study 23542809 — intervention group
Group type: COMPARATOR
Intervention: Mild cognitive impairment (MCI) patients during immediate recall of sequences of 5 items.
Number of subjects: 32
Study 23542809 — intervention group
Group type: COMPARATOR
Intervention: Mild cognitive impairment (MCI) patients during delayed recall.
Number of subjects: 32
Study 23542809 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI) patients immediate recall performance.
Number of subjects: 32
Study 23542809 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI) patients delayed recall performance.
Number of subjects: 32
Study 20714166 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer hydrochloride exposure
Number of subjects: 175
Study 20714166 — intervention group
Group type: COMPARATOR
Intervention: Control group (not exposed to sevelamer hydrochloride)
Number of subjects: 175
Study 19320662 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin plus high-dose metformin combination therapy (50 mg + 1000 mg twice daily)
Number of subjects: 1179
Study 19320662 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin plus low-dose metformin combination therapy (50 mg + 500 mg twice daily)
Number of subjects: 1179
Study 19320662 — intervention group
Group type: COMPARATOR
Intervention: Vildagliptin monotherapy (50 mg twice daily)
Number of subjects: 1179
Study 19320662 — intervention group
Group type: COMPARATOR
Intervention: High-dose metformin monotherapy (1000 mg twice daily)
Number of subjects: 1179
Study 19320662 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin plus high-dose metformin combination therapy
Number of subjects: 1179
Study 19320662 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin plus low-dose metformin combination therapy
Number of subjects: 1179
Study 16679331 — intervention group
Group type: EXPERIMENTAL
Intervention: Family style mealtimes
Number of subjects: 178
Study 16679331 — intervention group
Group type: COMPARATOR
Intervention: Usual individual pre‐plated service
Number of subjects: 178
Study 15561658 — intervention group
Group type: EXPERIMENTAL
Intervention: Tub bathing
Number of subjects: 102
Study 15561658 — intervention group
Group type: COMPARATOR
Intervention: Sponge bathing
Number of subjects: 102
Study 11411817 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20-50 mg/day)
Number of subjects: 324
Study 11411817 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 9103727 — intervention group
Group type: EXPERIMENTAL
Intervention: PD symptom levels
Number of subjects: 118
Study 9103727 — intervention group
Group type: EXPERIMENTAL
Intervention: PD diagnoses
Number of subjects: 118
Study 9103727 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in PD symptom levels
Number of subjects: 118
Study 9103727 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression of HIV infection
Number of subjects: 118
Study 8021335 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine (M-5041T), 6 mg applied for 3 days
Number of subjects: 8
Study 8021335 — intervention group
Group type: COMPARATOR
Intervention: Oral clonidine (Catapres), 0.075 mg every 12 hours for 3 days
Number of subjects: 8
Study 8021335 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal clonidine (M-5041T)
Number of subjects: 8
Study 8021335 — intervention group
Group type: COMPARATOR
Intervention: Oral clonidine (Catapres)
Number of subjects: 8
Study 2739347 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy
Number of subjects: 52
Study 2739347 — intervention group
Group type: COMPARATOR
Intervention: Control (no preoperative chemotherapy)
Number of subjects: 52
Study 2739347 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 31472393 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear glasses (no filter)
Number of subjects: 35
Study 31472393 — intervention group
Group type: COMPARATOR
Intervention: Orange glasses (filtering blue wavelength)
Number of subjects: 35
Study 31472393 — intervention group
Group type: EXPERIMENTAL
Intervention: White light
Number of subjects: 35
Study 31472393 — intervention group
Group type: COMPARATOR
Intervention: Orange light
Number of subjects: 35
Study 25175313 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-augmented pump (SAP) therapy
Number of subjects: 329
Study 25175313 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injection (MDI) therapy
Number of subjects: 329
Study 25175313 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor use
Number of subjects: 329
Study 23999956 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-session intervention including trauma-focused treatments (psychoeducation, cognitive restructuring, progressive muscle relaxation, development of trauma narrative) and infant redefinition
Number of subjects: 105
Study 23999956 — intervention group
Group type: COMPARATOR
Intervention: Active comparison group
Number of subjects: 105
Study 20615632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrahigh PSA levels (≥50 ng/ml)
Number of subjects: 2193
Study 20615632 — intervention group
Group type: EXPERIMENTAL
Intervention: Gleason grades of 8 to 10
Number of subjects: 2193
Study 18234129 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week exercise intervention
Number of subjects: 0
Study 18234129 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary restraint
Number of subjects: 0
Study 16765182 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical BCG therapy
Number of subjects: 4767
Study 16765182 — intervention group
Group type: COMPARATOR
Intervention: No BCG treatment (control group)
Number of subjects: 4767
Study 16765182 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG therapy with maintenance treatment
Number of subjects: 4767
Study 16765182 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG therapy for papillary carcinoma
Number of subjects: 4767
Study 16765182 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG plus chemotherapy/immunotherapy
Number of subjects: 4767
Study 12966127 — intervention group
Group type: EXPERIMENTAL
Intervention: Apheresis for multiple sclerosis
Number of subjects: 177
Study 12966127 — intervention group
Group type: EXPERIMENTAL
Intervention: Apheresis for thrombotic thrombocytopenic purpura
Number of subjects: 177
Study 12966127 — intervention group
Group type: EXPERIMENTAL
Intervention: Apheresis for myeloma cast nephropathy
Number of subjects: 177
Study 10880791 — intervention group
Group type: EXPERIMENTAL
Intervention: Externally-triggered (ET) task
Number of subjects: 7
Study 10880791 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-initiated (SI) task
Number of subjects: 7
Study 9552503 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser angioplasty
Number of subjects: 0
Study 9552503 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline infusion during excimer laser angioplasty
Number of subjects: 0
Study 1712282 — intervention group
Group type: EXPERIMENTAL
Intervention: Deviant stimuli (650 Hz, 70 dB, 20 msec)
Number of subjects: 10
Study 1712282 — intervention group
Group type: COMPARATOR
Intervention: Deviant stimuli (standard 600 Hz, 80 dB SPL, 50 msec)
Number of subjects: 10
Study 6840946 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% miconazole nitrate
Number of subjects: 15
Study 6840946 — intervention group
Group type: COMPARATOR
Intervention: 2.5% selenium disulfide
Number of subjects: 15
Study 31479530 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus reuteri lozenges, used twice-daily for 28 days as an adjunct to NSPT
Number of subjects: 59
Study 31479530 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges, used twice-daily for 28 days as an adjunct to NSPT
Number of subjects: 59
Study 31479530 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic Lactobacillus reuteri lozenges
Number of subjects: 59
Study 31479530 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 59
Study 28222678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg (Group D1)
Number of subjects: 75
Study 28222678 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 μg/kg (Group D2)
Number of subjects: 75
Study 28222678 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (Group D0)
Number of subjects: 75
Study 26890472 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting
Number of subjects: 2502
Study 26890472 — intervention group
Group type: COMPARATOR
Intervention: Endarterectomy
Number of subjects: 2502
Study 24518533 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program (12-week period, 3 times per week)
Number of subjects: 93
Study 24518533 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 93
Study 23059960 — intervention group
Group type: EXPERIMENTAL
Intervention: Tilt at ≥15°
Number of subjects: 157
Study 23059960 — intervention group
Group type: COMPARATOR
Intervention: Tilt at <15°
Number of subjects: 157
Study 23059960 — intervention group
Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 157
Study 19547873 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid chemoprophylaxis (300 mg/day) for six months
Number of subjects: 138
Study 19547873 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid chemoprophylaxis
Number of subjects: 138
Study 16787996 — intervention group
Group type: EXPERIMENTAL
Intervention: Bias-adjusted parameter estimator for the treatment coefficient
Number of subjects: 0
Study 16787996 — intervention group
Group type: EXPERIMENTAL
Intervention: Point estimator for treatment effect
Number of subjects: 0
Study 15310351 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth opening test
Number of subjects: 2
Study 15310351 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyromental distance test
Number of subjects: 2
Study 15310351 — intervention group
Group type: EXPERIMENTAL
Intervention: Head and neck movement test
Number of subjects: 2
Study 15310351 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular luxation test
Number of subjects: 2
Study 15310351 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of oropharyngeal view
Number of subjects: 2
Study 11642624 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of oral acyclovir treatment (80 mg/kg/day up to a maximum of 3,200 mg/day in four divided doses) starting within 24 hours of rash onset (Group A)
Number of subjects: 177
Study 11642624 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of acyclovir treatment starting on the first day of rash (Group B1)
Number of subjects: 177
Study 11642624 — intervention group
Group type: COMPARATOR
Intervention: 5 days of acyclovir treatment starting on the second day of rash (Group B2)
Number of subjects: 177
Study 11642624 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A subjects (acyclovir treatment within 24 hours of rash onset)
Number of subjects: 177
Study 9893537 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural analgesia
Number of subjects: 93
Study 9893537 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 93
Study 9374086 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 50 mg/m2 followed by paclitaxel 200 mg/m2 at intervals of 30 minutes, 4 hours, and 24 hours every 3 weeks
Number of subjects: 34
Study 9374086 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin 50 mg/m2 followed by paclitaxel 200 mg/m2
Number of subjects: 34
Study 2628366 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training 3 days/week for 10 weeks
Number of subjects: 117
Study 2628366 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training 3 days/week for 18 weeks
Number of subjects: 117
Study 2628366 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training 2 days/week for 10 weeks
Number of subjects: 117
Study 2628366 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training 2 days/week for 18 weeks
Number of subjects: 117
Study 2628366 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 117
Study 791447 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC-BCG
Number of subjects: 45
Study 791447 — intervention group
Group type: COMPARATOR
Intervention: FAC
Number of subjects: 45
Study 31649369 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Guide brochure and additional documents, n=40
Number of subjects: 86
Study 31649369 — intervention group
Group type: COMPARATOR
Intervention: Control group, n=40
Number of subjects: 86
Study 28127672 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated pillow
Number of subjects: 22
Study 24916651 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural corticosteroids (DepoMedrol™)
Number of subjects: 150
Study 24916651 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 150
Study 23148731 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg lacosamide oral tablet
Number of subjects: 16
Study 23148731 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg lacosamide oral syrup
Number of subjects: 16
Study 23148731 — intervention group
Group type: COMPARATOR
Intervention: Comparison of tablet and syrup formulations
Number of subjects: 16
Study 23148731 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations of lacosamide
Number of subjects: 16
Study 22130748 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised treatment in out-patients for schizophrenia (STOPS)
Number of subjects: 110
Study 22130748 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 110
Study 19387363 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval hypoxic training (15 sessions of passive intermittent hypoxia with 15-12% oxygen for 3-5 min periods)
Number of subjects: 18
Study 19387363 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (placebo group inhaled normoxic air)
Number of subjects: 18
Study 16760210 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 110
Study 16760210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 15144935 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 2289
Study 10641699 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX) injections
Number of subjects: 114
Study 10641699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 9309953 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressed group
Number of subjects: 0
Study 9309953 — intervention group
Group type: COMPARATOR
Intervention: Non-depressed participants
Number of subjects: 0
Study 8506790 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Behavioral Change with nicotine gum (Group SBCN)
Number of subjects: 450
Study 8506790 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured Behavioral Change without nicotine gum (Group SBC)
Number of subjects: 450
Study 8506790 — intervention group
Group type: COMPARATOR
Intervention: GP advice with nicotine gum (Group AN)
Number of subjects: 450
Study 8506790 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 450
Study 3317337 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 25 mg b.i.d.
Number of subjects: 26
Study 3317337 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg b.i.d.
Number of subjects: 26
Study 3317337 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of captopril and nifedipine
Number of subjects: 26
Study 3317337 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine
Number of subjects: 26